Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).

Sadahiro S, Sakamoto K, Tsuchiya T, Takahashi T, Ohge H, Sato T, Kondo K, Ogata Y, Baba H, Itabashi M, Ikeda M, Hamada M, Maeda K, Masuko H, Takahashi K, Sakamoto J, Kusano M, Hyodo I, Taguri M, Morita S

Open source

DOI: 10.1186/s12885-022-09267-z
Published: 2022 Feb 15
Container: BMC cancer
Publisher: figshare
Open access: yes

Credibility signals

uncertain Score 61/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-022-09267-z,
  title = {Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).},
  author = {Sadahiro S and Sakamoto K and Tsuchiya T and Takahashi T and Ohge H and Sato T and Kondo K and Ogata Y and Baba H and Itabashi M and Ikeda M and Hamada M and Maeda K and Masuko H and Takahashi K and Sakamoto J and Kusano M and Hyodo I and Taguri M and Morita S},
  year = {2022},
  journal = {BMC cancer},
  doi = {10.1186/s12885-022-09267-z},
  url = {https://doi.org/10.1186/s12885-022-09267-z}
}

RIS

TY  - JOUR
TI  - Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).
AU  - Sadahiro S
AU  - Sakamoto K
AU  - Tsuchiya T
AU  - Takahashi T
AU  - Ohge H
AU  - Sato T
AU  - Kondo K
AU  - Ogata Y
AU  - Baba H
AU  - Itabashi M
AU  - Ikeda M
AU  - Hamada M
AU  - Maeda K
AU  - Masuko H
AU  - Takahashi K
AU  - Sakamoto J
AU  - Kusano M
AU  - Hyodo I
AU  - Taguri M
AU  - Morita S
PY  - 2022
JO  - BMC cancer
DO  - 10.1186/s12885-022-09267-z
UR  - https://doi.org/10.1186/s12885-022-09267-z
ER  -

APA

S, S., K, S., T, T., T, T., H, O., T, S., K, K., Y, O., H, B., M, I., M, I., M, H., K, M., H, M., K, T., J, S., M, K., I, H., M, T., & S, M. (2022). Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201).. BMC cancer. https://doi.org/10.1186/s12885-022-09267-z

Source records

pubmed · retrieved 2026-09-26T07:32:00.442Z
europe-pmc · retrieved 2026-09-26T07:32:00.465Z
datacite · retrieved 2026-09-26T07:32:00.439Z
datacite · retrieved 2026-09-26T07:32:00.439Z
doaj · retrieved 2026-09-26T07:32:00.435Z